BRD2 and polycystic ovary syndrome: Similarly, in a comparison of r-hFSH with urinary gonadotropins (hMG or u-FSH) for ovulation induction in patients with polycystic ovary syndrome (PCOS), there was no difference in LBR (co-primary endpoint; five trials [505 patients]; OR 1.21, 95% CI 0.83, 1.78) or CPR (secondary endpoint; eight trials [1,330 patients]; OR 1.05, 95% CI 0.88, 1.27) with the two FSH preparations (90).